Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Refiles to correct day in paragraph 1 to Tuesday from Monday April 1 (Reuters) - Telehealth firm Hims & Hers Health HIMS.N said on Tuesday it plans to sell Eli Lilly's LLY.N weight-loss drug Zepbound on its platform. Shares of the company were up 8.5% in afternoon trading. (Reporting by Sneha S K in Bengaluru; Editing by Arun Koyyur) ((Sneha.SK@thomsonreuters.com;))
Recent news on LifeMD
See all newsLifeMD Q1 revenue beats estimates on record telehealth subscriber additons
Brief: LifeMD Q1 Adjusted EBITDA USD -4.5 Million Vs. IBES Estimate USD -4.66 Million
LifeMD rises after adding new daily obesity pill to weight management program
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US (updated)
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US